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a b s t r a c t
Enterovirus 71 (EV71) infection can induce encephalitis. Overt immune responses is suspected to cause
severe symptoms, so anti-inﬂammatory agents, corticosteroids have been recommended for treatment.
However, one clinical study reported that treatment with glucocorticoids, dexamethasone (Dex)
exacerbates disease severity. Here we investigated Dex treatment on EV71 infection using the murine
model and found that both long-term (14-day) and short-term (4-day) Dex treatment starting from 1 or
3 days postinfection increased the mortality and disease severity of infected mice. Dex treatment
starting from 4 or 8 days postinfection did not affect mouse mortality and disease severity. Early Dex
treatment starting from 1 day postinfection caused atrophy and enhanced apoptosis in lymphoid organs
to decrease the numbers of lymphocytes (CD4þ T cells, CD8þ T cells, and CD19þ B cells) and to increase
viral loads in infected tissues of mice. Our results demonstrate that Dex treatment has no beneﬁcial
effect on EV71 infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Enterovirus 71 (EV71) is a member of the family Picornaviridae.
EV71 infects humans by the fecal-oral route and can induce fever
and mild symptoms, such as herpangina or hand-foot-and-mouth
disease (Chang et al., 2007; Ho et al., 1999; Huang et al., 1999).
It can also infect the central nervous system (CNS) to induce
neurological manifestations, including aseptic meningitis, ence-
phalomyelitis, brainstem encephalitis, and acute ﬂaccid paralysis,
especially in young children. Brainstem encephalitis combined
with pulmonary edema complications often cause death or long-
term neurological sequelae (Chang et al., 2007). Widespread and
deadly EV71 outbreaks have been reported, particularly in the
Asia-Paciﬁc region, which are estimated to have infected millions
of children and have caused death and severe neurological
sequelae in thousands of children since the last decade (Qiu,
2008; Solomon et al., 2010). As vaccines and antiviral therapies
speciﬁc for EV71 are not available, EV71 infection is becoming
endemic in areas with outbreaks and has massive potential for
explosive epidemics.
Currently, there is no effective treatment for EV71-infected
patients with fatal symptoms, because the pathogenesis remains
elusive. Immature or insufﬁcient immunity has been suspected to
associate with increased morbidity and mortality in infected
patients, as infants and young children are highly susceptible to
fatal infection. The ﬁnding of lymphopenia with decreased levels
of CD4þ and CD8þ T cells in infected patients with brainstem
encephalitis and pulmonary edema supports this notion (Chang
et al., 2006; Wang et al., 2003a). However, some clinical studies
suggested that elevated cellular immunity with a predominance of
lymphocytes may be linked with unfavorable outcomes (Chang
et al., 2004; Hsia et al., 2005; Lum et al., 1998; Wang et al., 1999;
Yan et al., 2000). In addition, elevated cytokine and chemokine
levels are detected in encephalitis patients (Lin et al., 2002, 2003;
Wang et al., 2003a, 2006, 2008). Cytokine storm has therefore
been proposed to contribute to severe complications in infected
patients (Lin et al., 2002, 2003), so anti-inﬂammatory therapy
is recommended for treatment (Lin et al., 2002). Moreover, one
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report indicates that immunopathology may induce neurological
diseases and showed that late corticosteroid treatment about
three weeks after infection improved the neurological illness
(opso-myoclonus syndrome) of one patient (McMinn et al.,
2001). Later, another report of patients with pulmonary edema
and respiratory failure demonstrated that corticosteroid treatment
improves the long-term neurological deﬁcits of three patients
(Nolan et al., 2003). Nevertheless, one recent report with 134
cases ﬁnds that early use of glucocorticoids, such as dexametha-
sone (Dex), by rural practitioners to treat fever in outpatients is
associated with increased risk of severe disease or death in China
during 2008 outbreak (Ma et al., 2010). Steroid treatment is also
suspected to link with a signiﬁcant number of fatal cases in
Cambodia during 2012 outbreak (Seiff, 2012). Clinical reports
regarding the effect of corticosteroid treatment on EV71 disease
progression remains unclear. The present study was therefore
designed to examine the effect of Dex treatment in vivo because
of the paucity of reports on this issue. Using a murine infection
model, our results showed that early Dex treatment increases
EV71 lethality in mice, which may explain the increased mortality
of infected patients in China during 2008 outbreak and in
Cambodia during 2012 outbreak (Ma et al., 2010; Seiff, 2012).
Results
Early Dex treatment increases the mortality and tissue viral loads
of EV71-infected mice
It has been reported that the rural practitioners in village
clinics of China prescribed Dex to treat fever in child outpatients
during EV71 outbreak (Ma et al., 2010). We therefore tested Dex
treatment on infected mice that developed fever. Virus infection
induces viremia or interferon, which can induce fever. As it is
difﬁcult to measure temperature in mice, we used the presence of
viremia or interferon as the indication of fever in infected mice.
In the present study, 14-day-old C57BL/6J mice were infected with
8104 PFU/mouse of EV71. Infectious virus was detected in the
mouse blood with 4103, 1103, and 2102 PFU/ml at days 1, 4,
and 6 postinfection (p.i.), respectively. Additionally, our previous
report detected interferon-α in sera of infected mice from 10 min
to 3 days p.i. (Liu et al., 2005). Thus, we started Dex treatment
from day 1 p.i. A previous study showed that the effects of Dex on
herpes simplex virus-infected mice were depended on the timing
of the treatment (Sergerie et al., 2007). Dex treatment starting
from day 1 p.i. increased the mortality of infected mice, while Dex
treatment starting from day 3 p.i. reduced the mortality of infected
mice. This prompted us to treat mice with Dex (6.5 mg/kg/day in
one shot) at different time points after infection (from days 1, 3, 4,
or 8 to 14 p.i.) or with phosphate-buffered saline (PBS) from days
1 to 14 p.i. (Fig. 1A). There were eight to nice mice in each group.
The survival rates of infected mice treated with Dex starting from
days 4 or 8 p.i. or with PBS were comparable and about 90%
(Fig. 1B). Infected mice treated with Dex starting from day 3 p.i.
and, especially from day 1 p.i. displayed signs of encephalitis as
manifested by hunched posture, lethargy, hind limb paralysis, and
ataxia around days 5 to 6 p.i. (Fig. 1C) with ﬁnal survival rates of
50% and 12%, respectively, by day 30 p.i. (Fig. 1B). Dex treatment
starting from day 1 p.i. signiﬁcantly increased the mortality and
disease severity of infected mice when compared with PBS
treatment (po0.05). In separate experiments, tissues of infected
mice treated with PBS or Dex from day 1 p.i. (n¼3 to 6 samples
per time point in each group) were harvested to determine viral
titers (Fig. 1D). Viral titers in peripheral organs (heart, lung, liver,
intestine, kidney, spleen, and thymus), CNS tissues (brain without
the brainstem region, brain stem, and spinal cord), and blood of
Dex-treated mice were higher than those of PBS-treated mice
almost at all the time points (2, 4, 6, or 8 days p.i.) examined.
Short-term Dex treatment increases the mortality and tissue viral
loads of EV71-infected mice
Short-term (three- to four-day) Dex treatment was prescribed
by the rural practitioners in village clinics of China to treat fever in
child outpatients (Ma et al., 2010). We therefore tested the effect of
short-term Dex treatment by giving infected mice PBS (n¼9) or
Dex (n¼8) for 3 days from days 1 to 4 p.i. (Fig. 2A). All infected
mice treated with Dex succumbed to death within 14 days p.i.
(Fig. 2B) with a ﬁnal survival rate signiﬁcantly lower than that of
infected mice treated with PBS by 78% (po0.001). The disease
scores of infected mice treated with Dex were also signiﬁcantly
higher than those of infected mice treated with PBS (Fig. 2C;
po0.05). Viral titers in peripheral organs (heart, lung, liver,
intestine, kidney, and spleen) and CNS tissues (brain without the
brainstem region, brain stem, and spinal cord) of Dex-treated mice
were all higher than those of PBS-treated mice at days 6 and 8 p.i.
(Fig. 2D; n¼3 samples per time point in each group).
Early Dex treatment increases the mortality of severely infected mice
Dex treatment has been recommended for patients suffering from
severe symptoms, brainstem encephalitis and pulmonary edema
with a survival rate of less than 30% (Chang et al., 1999; Ho et al.,
1999). To determine the effect of Dex treatment on severely infected
mice with a low survival rate, we infected mice with a high viral dose
of 6105 PFU/mouse. Infected mice were treated with Dex from
days 1 or 4 to 14 p.i. or with PBS from days 1 to 14 p.i. (Fig. 3A). There
were eight, ten, and nine mice in each group, respectively. The
survival rates of infected mice treated with Dex from day 4 p.i. or
with PBS were comparable and about 30% (Fig. 3B). All infected mice
treated with Dex from day 1 p.i. succumbed to death within 10 days
p.i., with a survival rate signiﬁcantly lower than that of infected mice
treated with PBS (po0.001).
Dex treatment causes atrophy in lymphoid organs and reduces
lymphocyte numbers in infected organs
Previous studies showed that Dex reduced T and B cells
(Ashwell et al., 2000; Merino et al., 1994). In the present study,
we observed that the sizes of thymus and spleen were reduced in
Dex-treated mice. Therefore, we examined the effect of Dex
treatment starting from day 1 p.i. on the lymphoid organs of
mock-infected and infected mice. The thymus weights of PBS-
treated mice infected with or without EV71 were constant and
comparable from days 2 to 6 p.i. (at the age of 16–20 days old)
(Fig. 4A). Dex treatment signiﬁcantly decreased the thymus
weights of mock-infected and infected mice to a similar degree
from days 2 to 6 p.i. when compared with PBS treatment
(po0.05). The spleen weights of mock-infected mice treated with
PBS continued to increase from days 2 to 6 p.i. (Fig. 4B). EV71
infection did not affect the spleen weights from days 2 to 4 p.i., but
slightly decreased the weights at day 6 p.i. (p40.05). Dex treat-
ment signiﬁcantly decreased the spleen weights of mock-infected
and infected mice to a similar degree at days 4 and 6 p.i. when
compared with PBS treatment (po0.001).
Our previous report found that all three types of lymphocytes,
CD4þ T cells, CD8þ T cells, and B cells are important in protecting
mice from EV71 infection, as mice deﬁcient in any of these cells
displayed high mortality rates and tissue viral loads (Lin et al.,
2009; Wang et al., 2012). Because the spleen has all three types of
lymphocytes, we next determined the lymphocyte types and
levels in the mouse spleen affected by Dex treatment. Spleens of
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mock-infected and infected mice treated with PBS or Dex from day
1 p.i. were harvested at day 7 p.i., when elevated tissue viral loads
were detected in Dex-treated mice. Flow cytometric analyses
showed that Dex treatment alone or EV71 infection alone sig-
niﬁcantly decreased the mean numbers of CD4þ T cells, CD8þ
T cells, and CD19þ B cells in mouse spleens (Fig. 4C; po0.001).
Dex treatment further reduced levels of CD4þ T cells, CD8þ T cells,
and CD19þ B cells in spleens of infected mice when compared
with PBS treatment. We also quantiﬁed lymphocytes in the brain.
Results showed that EV71 infection increased the mean numbers
of CD4þ T cells, CD8þ T cells, and CD19þ B cells in brains at day
7 p.i. (Fig. 4D). Dex treatment reduced the inﬂux of all three types
of lymphocytes in brains of infected mice. Additional results
showed that short-term Dex treatment (from days 1 to 4 p.i.)
was as efﬁcient as the long-term Dex treatment in decreasing the
mean numbers of CD4þ T cells, CD8þ T cells, and CD19þ B cells in
spleens of infected mice when compared with PBS treatment at
day 7 p.i. (Fig. 5, po0.05).
Dex treatment and EV71 infection collaborates to enhance apoptosis
and to decrease the expression of anti-apoptotic factor Bcl-xL
in lymphoid organs
Previous studies showed that Dex induced apoptosis in T and B
cells (Andreau et al., 1998; Ashwell et al., 2000). We assessed
apoptosis in the spleens and thymuses of mock-infected and
infected mice treated with PBS or Dex from day 1 p.i. by detecting
the expression of cleaved caspase-3, an apoptosis marker, using
western blotting. In the mouse spleen, Dex treatment alone or
EV71 infection alone slightly increased cleaved caspase-3 levels at
day 4 p.i. (Fig. 6A; p40.05). Dex treatment signiﬁcantly increased
the cleaved caspase-3 level in infected mice when compared with
Fig. 1. Early Dex treatment increases the mortality, disease severity, and tissue viral loads of infected mice. (A) Mice infected with 8104 PFU/mouse of EV71 were given one
shot per day of PBS (n¼9) from day 1 postinfection (p.i.) or Dex (6.5 mg/kg) from day 1 (1 d.p.i.; n¼8), day 3 (3 d.p.i.; n¼8), day 4 (4 d.p.i.; n¼8), or day 8 (8 d.p.i.; n¼8) to
day 14 p.i. Mouse survival rates (B) and disease scores (C) at the indicated times are shown. (B) npo0.05 and nnnpo0.001, via a log-rank test. NS, not statistically signiﬁcant.
(C) Data show means7SE (error bars). npo0.05, via a Wilcoxon signed-rank test. (D) Tissue viral titers of mice treated with PBS or Dex from day 1 p.i. were determined at
the indicated times. Data show means7SE (error bars) of three to six samples per data point. npo0.05 and nnpo0.01, via a Mann–Whitney U test compared with samples
harvested from PBS-treated mice at the same time point.
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Dex treatment alone or EV71 infection alone (po0.05). Similar
results were observed in the mouse thymus at day 2 p.i. (Fig. 6B).
Results of cleaved caspase-3 obtained from the thymus and spleen
showed that Dex treatment and EV71 infection collaborates to
enhance apoptosis in lymphoid organs. We also measured the
expression of cleaved caspase-3 levels in spleen lymphocytes. Flow
cytometric analyses detected enhanced levels of cleaved caspase-3
in CD4þ T cells, CD8þ T cells, and CD19þ B cells in the spleen of
infected mice treated with Dex when compared with mock-
infected mice treated with PBS at day 4 p.i. (Fig. 6C; po0.01),
showing that enhanced apoptosis was observed in all three types
of lymphocytes.
As Dex has been shown to induce apoptosis by decreasing the
expression of anti-apoptotic factor, Bcl-xL in human B (acute
lymphoblastic leukemia) cell lines (Laane et al., 2007), we there-
fore assayed the Bcl-xL level in the spleen. Dex treatment alone or
EV71 infection alone decreased spleen Bcl-xL levels with a
signiﬁcant difference found in EV71 infection when compared
with mock-infected mice treated with PBS (Fig. 6D; po0.05). Dex
treatment further and signiﬁcantly increased the spleen Bcl-xL
level in infected mice when compared with Dex treatment alone
or EV71 infection alone (po0.05).
The effects of Dex treatment on cytokine and chemokine expression
in the serum and brain of infected mice vary
High levels of cytokines and chemokines detected in EV71-
infected patients with brainstem encephalitis (Lin et al., 2002,
Fig. 2. Short-term Dex treatment increases the mortality, disease severity, and tissue viral loads of infected mice. (A) Mice infected with 8104 PFU/mouse of EV71 were
given one shot per day of PBS (n¼9) or Dex (n¼8) from days 1 to 4 postinfection. Mouse survival rates (B) and disease scores (C) at the indicated times are shown.
(B) nnnpo0.001, via a log-rank test. (C) Data show means7SE (error bars). npo0.05, via a Wilcoxon signed-rank test. (D) Tissue viral titers of PBS- or Dex-treated mice were
determined at the indicated times. Data show means7SE (error bars) of three samples per data point. npo0.05 and nnpo0.01, via a Mann–Whitney U test compared with
samples harvested from PBS-treated mice at the same time point.
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2003; Wang et al., 2003a, 2006, 2008) has promoted the recom-
mendation of using anti-inﬂammatory therapy for treatment
(Lin et al., 2002). We therefore examined the effects of Dex
treatment starting from day 1 p.i. on cytokine and chemokine
expression in infected mice. Dex treatment increased the serum
interleukin (IL)-6 level at day 4 p.i. and brain IL-6 levels at days
4 and 6 p.i. in infected mice with signiﬁcant differences found at
day 4 p.i. for both serum and brain IL-6 levels when compared
with PBS treatment (Fig. 7A B; po0.05). Dex treatment reduced
serum levels of antiviral cytokine, interferon (IFN)-β in infected
mice at days 2 and 4 p.i. (Fig. 7C), although the differences did not
reach statistical signiﬁcance when compared with PBS treatment.
The brain IFN-β levels of infected mice treated with Dex or PBS
were comparable at days 2 and 4 p.i. (Fig. 7D). The serum and
brain IFN-γ levels in infected mice treated with Dex or PBS were
not signiﬁcantly different at days 4 and 6 p.i. (data not shown).
Dex treatment signiﬁcantly increased the serum CXC chemokine
ligand 10 (CXCL10; IFN-γ-inducible protein 10 [IP-10]) level at day
4 p.i. and brain CXCL10 levels at days 4 and 6 p.i. in infected mice
when compared with PBS treatment (Fig. 7E F; po0.05). Dex
treatment signiﬁcantly increased the serum level of chemokine (C-
C motif) ligand 5 (CCL5), also known as RANTES (regulated on
activation, normal T cell expressed and secreted), at day 4 p.i., but
signiﬁcantly reduced the serum CCL5 level at day 2 p.i. and the
brain CCL5 level at day 6 p.i. in infected mice when compared with
PBS treatment (Fig. 7G H; po0.05).
Discussion
Previous clinical reports regarding the effect of corticosteroid
treatment on EV71 disease progression are unclear. The present
study using the murine model shows that early Dex treatment
starting from days 1 or 3 p.i. increased the mortality, disease
severity, and tissue viral loads of infected mice. Additionally, late
Dex treatment starting from days 4 or 8 p.i. failed to improve the
disease severity of infected mice. Our results provide evidence that
Dex treatment has no beneﬁcial effect on EV71 infection in mice.
Dex is a potent anti-inﬂammatory steroid used in the clinic.
In EV71-infected patients, up to 50 mg/kg/day of Dex has been used
to treat fever (Ma et al., 2010). Dex usage at the dose of 10 mg/kg/day
has been shown to affect the survival of herpes simplex virus-infected
mice (Sergerie et al., 2007). We have tested two doses (6.5 and 1.5 mg/
kg/day), and both doses failed to affect the body weight and survival of
mock-infected mice. Early treatment with Dex at the dose of 6.5 mg/
kg/day, but not of 1.5 mg/kg/day, increased the mortality of infected
mice, so the dose of 6.5 mg/kg/day was used for further investigation.
Our mouse results are consistent with the recent clinical ﬁnding,
which showed that early use of glucocorticoids, Dex to treat fever in
outpatients is associated with increased risk of severe disease or death
(Ma et al., 2010). During the ﬁrst three days of EV71 infection in mice,
viral tiers in CNS tissues were increased (Fig. 1D), the spleen weight
continued to increase (Fig. 4B), and the serum level of antiviral
cytokine (IFN-β) was elevated (Fig. 7C), when compared with mea-
surements from days 4 or 8 p.i. These results could explain why Dex
treatment starting from days 1 or 3 p.i., but not from days 4 or 8 p.i.,
increased the mortality rates of infected mice.
Our previous report showed that all three types of lymphocytes
(CD4þ T cells, CD8þ T cells, and B cells) function in decreasing the
mortality and tissue viral loads of infected mice (Lin et al., 2009).
In addition, we observed spleen atrophy and reduced lymphocyte
numbers in the spleen of infected mice (Shen et al., 2013; Wang et al.,
2004), while elevated lymphocyte numbers were detected in the
non-lymphoid organ, such as the brain, of infected mice (Lin et al.,
2009; Shen et al., 2013). In the past, we assumed that the reduced
lymphocyte numbers in the spleen were due to the migration of
lymphocytes to non-lymphoid organs of infected mice. However, in
this study, we were surprised to ﬁnd that EV71 infection induced
apoptosis in lymphoid organs effectively when compared with Dex
treatment, a known apoptosis inducer of lymphocytes (Fig. 6A and B).
Moreover, Dex further enhanced apoptosis in lymphoid organs and
reduced CD4þ T cells, CD8þ T cells, and B cells in infected organs of
mice, showing why Dex treatment increased the mortality and tissue
viral loads of EV71-infected mice.
EV71 has been shown to infect lymphocytes in human periph-
eral blood mononuclear cells as determined by the expression of
viral antigen on the cell surface (Chen and Yeh, 2009). EV71 has
also been shown to replicate in human T cell lines, such as Jurkat T
cells (Nishimura et al., 2009). In mice, we assessed whether EV71
can infect T cells in vivo by detecting the expression of viral
antigen on the surface of CD4 and CD 8 T cells in the spleen of
infected mice using ﬂow cytometry, but we failed to detect it. Our
unpublished results found that EV71 infection can activate lym-
phocytes in vivo by enhancing the expression of CD69 (activation
marker) on the surface of CD4 and CD 8 T cells and the expression
of CD138 (activation marker) on the surface of CD19-postivie B
cells in the spleen of infected mice. Lymphocyte activation can
lead to cell death due to apoptosis (Green et al., 2003). Accord-
ingly, it is very likely that EV71 infection causes apoptosis of
lymphoid cells by promoting activation-induced cell death.
Dex has been shown to induce apoptosis by decreasing the
expression of anti-apoptotic factor, Bcl-xL in human B cell lines
(Laane et al., 2007) and by enhancing the expression of pro-
apoptotic factor, Bim in T-cell lymphoma lines (Wang et al.,
2003b). EV71 infection has been shown to induce apoptosis by
increasing the expression of pro-apoptotic factor, Bax in the
human (RD) cell line (Sun et al., 2011). Surprisingly, we found
comparable levels of Bim and Bax in the spleens of mock-infected
mice and infected mice treated with or without Dex by western
blotting (data not shown). Of note, both Dex and EV71 infection
reduced Bcl-xL expression. Moreover, Dex and EV71 infection
collaborated to further decrease Bcl-xL expression. These results
suggest that Dex alone, EV71 infection alone, and Dex plus EV71
infection may induce apoptosis by reducing Bcl-xL expression in
Fig. 3. Early Dex treatment increases the mortality of severely infected mice.
(A) Mice infected with 6105 PFU/mouse of EV71 were treated with PBS (n¼9)
from day 1 postinfection or with Dex from day 1 (1 d.p.i.; n¼8) or day 4 (4 d.p.i.;
n¼10) to day 14 postinfection. (B) Mouse survival rates at the indicated times are
shown. nnnpo0.001, via a log-rank test.
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mouse lymphoid organs in a mechanism, which is different from
those reported previously by in vitro studies (Laane et al., 2007;
Sun et al., 2011; Wang et al., 2003b).
Anti-inﬂammatory therapy has been recommended to treat
EV71-infected patients with severe symptoms, as high levels of
cytokines, such as IL-6 and IFN-γ, are detected in brainstem
Fig. 4. The effects of Dex treatment or/and EV71 infection on lymphoid organ weights and lymphocyte levels in infected organs. Mice were infected with 8104 PFU/mouse
of EV71 (EV71) or mock-infected (Mock) and given one shot per day of PBS or Dex from day 1 postinfection (p.i.). The weights of thymus (A) and spleen (B) at the indicated
times are shown. The numbers of CD4þ T cells, CD8þ T cells, and CD19þ B cells in the spleen (C) and brain (D) at day 7 p.i. were determined by ﬂow cytometry. Data show
means7SE (error bars) of three to nine samples per data point or group. npo0.05, nnpo0.01, and nnnpo0.001, via a Student t test compared with samples harvested from
mock-infected mice treated with PBS at the same time point (A and B) or between the indicted groups (C and D).
Fig. 5. Early and short-term Dex treatment decreases spleen lymphocyte levels of infected mice. Mice infected with 8104 PFU/mouse of EV71were given one shot per day
of PBS or Dex from days 1 to 4 postinfection. The numbers of CD4þ T cells, CD8þ T cells, and CD19þ B cells in spleens of mice at day 7 postinfection are shown. Data show
means7SE (error bars) of three samples per group. npo0.05, via a Student t test.
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encephalitis patients (Lin et al., 2002, 2003; Wang et al., 2003a,
2006, 2008). In mice, pro-inﬂammatory cytokine IL-6 is shown to
contribute to EV71 pathogenesis, as depletion of IL-6 using the
speciﬁc antibody increases the survival of infected mice (Khong
et al., 2011). Dex has been shown to decrease both IFN-β and IFN-γ
mRNA levels in the brain of herpes simplex virus-infected mice
(Sergerie et al., 2007). Here we showed that, for cytokines, Dex
increased both serum and brain IL-6 levels, reduced the serum
level of antiviral cytokine (IFN-β), and failed to affect both serum
and brain IFN-γ levels. For chemokines, Dex increased both serum
and brain CXCL-10 levels and the serum CCL5 level, but decreased
the brain CCL5 level. The effects of Dex on cytokine and chemokine
expression varied, depending upon the particular cytokine or
chemokine and infection time points examined. For cytokines,
Dex increased IL-6 levels and reduced the IFN-β level, which may
justify the high mortality rate and tissue viral loads observed in
EV71-infected mice treated with Dex. Regarding how EV71 causes
death in the infected host, cytokines are shown to be involved, as
IL-6 increases the mortality of infected mice (Khong et al., 2011).
In addition, it has been proposed that the neuronal infection by
virus, especially in the brain stem may be sufﬁcient (Chang et al.,
1998; Lum et al., 1998). Destruction of the medullary cardiore-
spiratory center is believed to be largely responsible. Here we
show again that both the cytokine and the neuronal infection by
virus are two important causes of death, as Dex treatment
increases the lethality of infected mice with elevated viral titers
in the brain stem and IL-6 levels.
Previous and present studies found that infected mice and
patients are analogous in the aspects, which were examined in this
report. They display similar disease progression with signs of CNS
infection (encephalitis) as manifested by ataxia and limb paralysis
before death (Fig. 1C) (McMinn et al., 2001). Abundant virus
(Fig. 1D), viral antigens, CD4þ T cells, CD8þ T cells, and B cells
(Fig. 4) are detected in the brains (Lin et al., 2009). Elevated
cytokine and chemokine levels are found in the sera and brains
(Khong et al., 2011; Lin et al., 2002, 2003; Shen et al., 2013;
Fig. 6. The effects of Dex treatment or/and EV71 infection on cleaved caspase-3 and Bcl-xL expression in mouse lymphoid organs. Mice were infected with 8104 PFU/
mouse of EV71 (þ) or mock-infected () and given one shot per day of PBS () or Dex (þ) from day 1 postinfection. Mouse spleens were harvested at day 4 postinfection
and mouse thymuses were harvested at day 2 postinfection to determine cleaved caspase-3 (A and B), Bcl-xL (D), and actin levels by western blotting. Top panels show
representative blots and bottom panels show quantitated results. The protein levels of mock-infected mice treated with PBS were set as 1. (C) The mean ﬂuorescence
intensities (MFI) of cleaved caspase-3 in spleen CD4þ T cells, CD8þ T cells, and CD19þ B cells were determined by ﬂow cytometry. Data showmeans7SE (error bars) of three
to nine samples per group. npo0.05, nnpo0.01, and nnnpo0.001, via a Student t test.
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Wang et al., 2008). The present mouse study found the following.
Early Dex treatment increased the mortality, disease severity, and
tissue viral loads of infected mice, which is consistent with the
increased risk of severe disease or death of infected patients
treated with steroids in China during 2008 outbreak and in
Cambodia during 2012 outbreak (Ma et al., 2010; Seiff, 2012).
Dex further enhanced apoptosis in infected lymphoid organs and
reduced lymphocyte numbers in infected organs. Our results raise
caution over the malpractice of using corticosteroids for infected
patients and also help the clinician to assess the risk of such
practice. Currently, there is no effective treatment for EV71-
infected patients with fatal symptoms. Intravenous immunoglo-
bulin (IVIG) has been used for treatment in countries like Taiwan
(Wang et al., 2006). Our previous studies and unpublished results
demonstrated that virus-speciﬁc antibody, but not IVIG, given
before or after infection efﬁciently reduces the mortality, disease
severity, and tissue viral loads of infected mice (Lin et al., 2009;
Wang et al., 2012). Therefore, instead of Dex and IVIG, vaccines and
EV71-speciﬁc antibody should be better strategies for controlling
deadly outbreaks and disease progression in patients.
Materials and methods
The cell, virus, and mice
Human rhabdomyosarcoma (RD) cell line was maintained and
propagated according to the instructions of the American Type
Culture Collection. EV71 strain M2 was propagated and titrated on
RD cell monolayers and used to infect mice as previously described
(Li et al., 2008). All mouse experiment protocols were approved by
the Laboratory Animal Committee of National Cheng Kung Uni-
versity. C57BL/6J mice were purchased from the National Labora-
tory Animal Center in Taiwan, bred, and maintained under
speciﬁc-pathogen-free conditions in the Animal Center of our
college.
Infection and Dex treatment of mice
Fourteen-day-old male and female mice were infected with
8104 or 6105 PFU/mouse of EV71 strain M2 or mock-infected
with lysates of uninfected RD cells by intraperitoneal inoculation.
Subsequently, mice were given one shot of PBS or Dex (6.5 mg/kg)
per day by intraperitoneal injection. The survival of infected
mice was monitored. The disease score was graded as follows:
0, healthy; 1, rufﬂed hair; 2, weakness in hind limbs; 3, paralysis in
a single hind limb; 4, paralysis in both hind limbs; and 5, death.
In separate experiments, mice were anesthetized before mouse
blood was collected. Then the mice were perfused by intracardial
injection of ice-cold PBS, and mouse tissues were harvested.
Mouse blood was frozen and sonicated. Mouse tissues were frozen,
homogenized, frozen, and sonicated. The resulting samples were
assayed for viral titers by plaque assay using RD cell monolayers.
Flow cytometry
Spleens and brains were harvested from mice perfused with
PBS. Mouse spleens were homogenized, treated twice with buffer
to lyse red blood cells, and washed with RPMI medium containing
10% fetal bovine serum. Mouse brains were harvested and homo-
genized in PBS containing 0.01 M EDTA and 0.2% bovine serum
albumin. The brain homogenates were passed through strainer
ﬁlters (BD Biosciences). Brain leukocytes were puriﬁed by
Percoll (GE Healthcare) gradient centrifugation. Freshly isolated
leukocytes from mouse spleens and brains were stained with
ﬂuorescein isothiocyanate- or phycoerythrin-conjugated control
antibodies or antibodies against mouse lymphocyte antigens, CD4
(clone GK 1.5; eBioscience), CD8a (clone 53-6.7; eBioscience), or
CD19 (clone 6D5; eBioscience) for 45 min on ice. For detection of
Fig. 7. The effects of Dex treatment on cytokine and chemokine expression in the serum and brain of infected mice. Mice infected with 8104 PFU/mouse of EV71 were
given one shot per day of PBS or Dex from day 1 postinfection. Levels of cytokines, IL-6 (A and B) and IFN-β (C and D), and chemokines, CXCL10 (E and F) and CCL5 (G and H),
in the serum and brain of infected mice at the indicated times were determined by ELISA. Data show means7SE (error bars) of three samples per data point. npo0.05,
nnpo0.01, and nnnpo0.001, via a Student t test compared with samples harvested from PBS- or Dex-treated mice at the same time point.
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cleaved caspase-3 in lymphocytes, freshly isolated leukocytes from
mouse spleens were stained with phycoerythrin-conjugated con-
trol antibodies or antibodies against mouse leukocyte antigens,
CD4, CD8a, or CD19 for 45 min on ice. Subsequently, cells were
ﬁxed with 2% formaldehyde, washed with PBS containing 0.5%
bovine serum albumin, and stained with antibody against mouse
cleaved caspase-3 (clone Asp175; Cell signaling) before cells were
incubated with the ﬂuorescein isothiocyanate-conjugated second-
ary antibody. The stained cells were analyzed by a FACSCalibur (BD
Biosciences) using WinMDI software.
Western blotting
Mouse thymuses were homogenized, washed with PBS, and
treated with cell lysis buffer (Cell signaling). Mouse spleens were
homogenized, treated twice with buffer to lyse red blood cells,
washed with RPMI medium containing 10% fetal bovine serum and
then with PBS, and treated with cell lysis buffer. Cell lysates were
separated by 12% SDS and transferred to membranes. Membranes
were probed with antibodies against mouse cleaved caspase-3
(clone Asp175), Bcl-xL (Cell signaling), or β-actin (clone C4;
Millipore) followed by donkey anti-rabbit or anti-mouse second-
ary antibodies conjugated with horseradish peroxidase (Jackson
ImmunoResearch Laboratories, Inc). The protein bands were
developed using an enhanced chemiluminescence kit (Millipore).
Cytokine and chemokine measurement
Mouse blood was processed into serum. Brains harvested from
mice perfused with PBS were frozen at 80 1C for more than 2 h,
thawed, and homogenized in PBS containing protease inhibitor
cocktail (Sigma-Aldrich). The brain homogenates were centrifuged
to obtain supernatants. The sera and brain supernatants were
subjected to enzyme-linked immunosorbent assays (ELISAs) to
measure mouse CCL5, CXCL10, IL-6 (R&D Systems), and IFN-β (PBL
InterferonSource) using commercially available kits according to
the manufacturer's instructions.
Statistical analyses
Data are expressed as means7standard errors (SE). For statis-
tical comparison, Kaplan–Meier survival curves were analyzed by
a log-rank test, disease scores were analyzed by a Wilcoxon
signed-rank test, and tissue viral titers were analyzed by a
Mann–Whitney U test. The rest of data were analyzed by a Student
t test. All p values are for two-tailed signiﬁcance tests. A p value of
o0.05 is considered statistically signiﬁcant.
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